Yuji Murakami1, Ippei Takahashi2, Ikuno Nishibuchi3, Yoshiko Doi4, Tomoyuki Okabe5, Masahiro Kenjo6, Tomoki Kimura7, Yasushi Nagata8. 1. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. yujimura@hiroshima-u.ac.jp. 2. Department of Radiation Oncology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, Hiroshima, 730-8619, Japan. ippei@hiroshima-u.ac.jp. 3. Department of Radiation Oncology, Hiroshima Prefectural Hospital, Ujinakanda Minami-ku, Hiroshima, 734-8530, Japan. ikuno@hiroshima-u.ac.jp. 4. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. yoshikod@hiroshima-u.ac.jp. 5. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. t-okabe1115@hiroshima-u.ac.jp. 6. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. kenjom@hiroshima-u.ac.jp. 7. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. tkimura@hiroshima-u.ac.jp. 8. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. nagat@hiroshima-u.ac.jp.
Abstract
BACKGROUND: The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed. METHODS: Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60 Gy/30 fractions (range, 54-66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-furuorouracil-based chemotherapy. RESULTS: Thirty-six patients (33 men and 3 women) aged from 45 to 80 years (median, 67 years) were assessed. All patients had squamous cell carcinoma. With a median follow-up time of 61 months, the 5-year overall survival, disease-free survival, and locoregional failure-free survival rates were 86 % [95 % confidence interval (CI), 74-99 %], 59 % (95 % CI, 42-77 %), and 90 % (95 % CI, 79-100 %), respectively. Late toxicities of grade 3 pleural effusion in 2 patients, grade 4 pericardial effusion in 1 patient, and grade 5 pneumonitis in 1 patient were observed. Metachronous esophageal cancer was observed in 8 patients (22 %). Among them, 6 patients with mucosal legions were salvaged by endoscopic resection. CONCLUSION: Our long-term results of concurrent chemoradiotherapy (CCRT) for patients with esophageal submucosal cancer showed acceptable toxicities and favorable locoregional control and survivals while maintaining organ preservation.
BACKGROUND: The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed. METHODS:Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60 Gy/30 fractions (range, 54-66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-furuorouracil-based chemotherapy. RESULTS: Thirty-six patients (33 men and 3 women) aged from 45 to 80 years (median, 67 years) were assessed. All patients had squamous cell carcinoma. With a median follow-up time of 61 months, the 5-year overall survival, disease-free survival, and locoregional failure-free survival rates were 86 % [95 % confidence interval (CI), 74-99 %], 59 % (95 % CI, 42-77 %), and 90 % (95 % CI, 79-100 %), respectively. Late toxicities of grade 3 pleural effusion in 2 patients, grade 4 pericardial effusion in 1 patient, and grade 5 pneumonitis in 1 patient were observed. Metachronous esophageal cancer was observed in 8 patients (22 %). Among them, 6 patients with mucosal legions were salvaged by endoscopic resection. CONCLUSION: Our long-term results of concurrent chemoradiotherapy (CCRT) for patients with esophageal submucosal cancer showed acceptable toxicities and favorable locoregional control and survivals while maintaining organ preservation.
Entities:
Keywords:
Chemoradiotherapy; Esophageal cancer; Submucosal cancer
Authors: P Maingon; A d'Hombres; G Truc; I Barillot; C Michiels; L Bedenne; J C Horiot Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-01 Impact factor: 7.038
Authors: M al-Sarraf; K Martz; A Herskovic; L Leichman; J S Brindle; V K Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami Journal: J Clin Oncol Date: 1997-01 Impact factor: 44.544
Authors: Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-03 Impact factor: 7.038
Authors: Nasser K Altorki; Paul C Lee; Yaakov Liss; Danish Meherally; Robert J Korst; Paul Christos; Madhu Mazumdar; Jeffrey L Port Journal: Ann Surg Date: 2008-03 Impact factor: 12.969
Authors: T Mizumoto; T Hiyama; S Oka; N Yorita; K Kuroki; M Kurihara; Y Yoshifuku; Y Sanomura; Y Urabe; Y Murakami; K Arihiro; S Tanaka; K Chayama Journal: Dig Dis Sci Date: 2018-03-21 Impact factor: 3.199